Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the stock.

Oragenics Stock Down 2.1 %

Shares of Oragenics stock opened at $0.25 on Thursday. Oragenics has a twelve month low of $0.24 and a twelve month high of $3.43. The company’s 50 day moving average is $0.29 and its 200 day moving average is $0.35. The company has a market cap of $3.11 million, a price-to-earnings ratio of -0.04 and a beta of 0.85.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.